Issues
-
Cover Image
Cover Image
Zebrafish are a popular model organism for studying embryonic vascular development. Recent studies have shown that clinical stage anti-angiogenic compounds can inhibit vascular growth in zebrafish. In this issue, Tran and colleagues sought to use zebrafish as a tool to discover new anti-angiogenic compounds. Transgenic zebrafish expressing a green fluorescent reporter protein specifically in the vasculature were employed to develop an automated, quantitative screening assay for anti-angiogenic compound activity. The methods developed include automated determination of angiogenic blood vessel count in the trunk of zebrafish embryos. The assay was used to screen a 1280 compound library. Two known anti-angiogenic compounds were identified in the screen. Additionally, a novel anti-angiogenic compound, indirubin-3’-monoxime, was discovered. These results show that zebrafish can be used as a drug discovery tool to identify newanti-angiogenic compounds. For details, see the article by Tran and colleagues on page 11386 of this issue. - PDF Icon PDF LinkTable of Contents
Cancer Research
Table of Contents
Reviews
Meeting Report
Priority Reports
Cells Deficient in the FANC/BRCA Pathway Are Hypersensitive to Plasma Levels of Formaldehyde
Variants on 9p24 and 8q24 Are Associated with Risk of Colorectal Cancer: Results from the Colon Cancer Family Registry
Molecular Biology, Pathobiology, and Genetics
Direct Transcriptional Activation of Promyelocytic Leukemia Protein by IFN Regulatory Factor 3 Induces the p53-Dependent Growth Inhibition of Cancer Cells
CD83 Gene Polymorphisms Increase Susceptibility to Human Invasive Cervical Cancer
Cell, Tumor, and Stem Cell Biology
Neuroblastoma Cells Isolated from Bone Marrow Metastases Contain a Naturally Enriched Tumor-Initiating Cell
Delta-like 4 Notch Ligand Regulates Tumor Angiogenesis, Improves Tumor Vascular Function, and Promotes Tumor Growth In vivo
Experimental Therapeutics, Molecular Targets, and Chemical Biology
Genetic Alterations in the Tyrosine Kinase Transcriptome of Human Cancer Cell Lines
Immunology
Epidemiology
Prevention
3′-Deoxy-3′-[18F]Fluorothymidine Positron Emission Tomography Is a Sensitive Method for Imaging the Response of BRAF-Dependent Tumors to MEK Inhibition
Correction
Journal Archive
Cancer Research
(1941-Present; volumes 1-current)Published twice monthly since 1987. From 1941-1986, published monthly.
(ISSN 0008-5472)
The American Journal of Cancer
(1931-1940; volumes 15-40)Published quarterly in 1931, bimonthly in 1932, and monthly from 1933 to 1940. The journal changed title to Cancer Research in 1941.
(ISSN 0099-7374)
The Journal of Cancer Research
(1916-1930); volumes 1-14)Published quarterly from 1916 through 1930 (publication was suspended from November 1922 to March 1924). The journal changed title to The American Journal of Cancer in 1931.
(ISSN 0099-7013)
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.